Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Status:
Terminated
Trial end date:
2020-12-18
Target enrollment:
Participant gender:
Summary
The purpose of this study was to characterize the safety, tolerability, pharmacokinetics,
pharmacodynamics and antitumor activity of MIW815 (ADU-S100) in combination with PDR001.